Ventricular arrhythmias and sudden death in patients taking ibrutinib

著者: Benjamin L. Lampson, Lijian Yu, Robert J. Glynn, Jacqueline C. Barrientos, Eric D. Jacobsen, Versha Banerji, Jeffrey A. Jones, Renata Walewska, Kerry J. Savage, Gregory F. Michaud, Javid J. Moslehi, Jennifer R. Brown - Blood 2017 被引用: 209

To the editor: Ibrutinib, approved by the US Food and Drug Administration (FDA), is an inhibitor of Bruton tyrosine kinase (BTK).[1][1][⇓][2][⇓][3][⇓][4]-[5][5] Ibrutinib use is associated with atrial fibrillation (AF), with an incidence of 5% to 6% after 18 months on therapy[4][4][⇓][5]-[6